compensation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Pascal Soriot, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about AstraZeneca
compensation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Pascal Soriot, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window. The 5 average consequence score is below the beat benchmark of 5.6 in the same window. AstraZeneca appears in 1 tracked HR & Workforce story from February 24, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 HR & Workforce stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering AstraZeneca. Shared-story counts are live from our verified record — not editorial picks.
AstraZeneca CEO Pascal Soriot’s total remuneration for 2025 reached £17.7 million, driven by strong corporate performance and long-term incentives. The payout highlights the ongoing tension between UK executive pay standards and the global competition for pharmaceutical leadership talent.